Crystagen is a synthetic Khavinson peptide bioregulator marketed for immune support, usually supplied as a 20 mg subcutaneous formulation. Clinician protocols dose it at 20 mg subcutaneously, though the guidance here rests on a single source. The tradeoff to know up front: there is no FDA-approved indication, so all human use is off-label or compounded, and there is no meaningful body of community reports to draw on yet.
Data last updated
Measured on 1 of 6 axes
Evidence shape
No human trials or published studies exist for Crystagen. There are no registered trials, no mapped indications, and no completed research to evaluate. The peptide remains unstudied in humans.
Human evidence
No human study rows have been captured for this peptide yet.
Lower-tier support
No animal or in-vitro support rows have been captured yet.
Published literature
The research corpus was searched; no standalone peptide-level publications were indexed beyond the trials and preclinical rows above.
Source data
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
Symptom-relevant clinical or community evidence has not been captured for this peptide yet.
price offers can be sorted by column · 1 out-of-stock offer not shown
How Crystagen is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
No structured protocol details captured for this tier yet.
In the clinician practice tier, the reported dose is 20 mg administered subcutaneously on a daily basis, with no specified cycling schedule.
No structured protocol details captured for this tier yet.